Akari Therapeutics, Plc (AKTX)Healthcare | Biotechnology | Tampa, United States | NasdaqCM
13.42 USD
+0.02
(0.149%)
⇧
(July 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 2:42 a.m. EDT
The investment case here is structurally broken. The company is burning through cash with no revenue, a massive debt-to-equity ratio, and a balance sheet that cannot support operations without constant dilution. The price history confirms a catastrophic failure, having lost 99.5% of its value over the last nine years with five consecutive years of decline. While recent headlines about cancer data and capital raises created a temporary spike, the underlying business fundamentals remain non-existent. The options market is screaming 'sell,' with traders buying deep out-of-the-money puts to protect against further collapse. This is not a turnaround story; it is a distressed biotech with no path to profitability visible in the data. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.719344 |
| AutoARIMA | 0.719348 |
| MSTL | 0.720684 |
| AutoTheta | 0.958517 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 1.38 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.034 |
| Excess Kurtosis | -0.45 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.09 |
| Market Cap | 23,490,502 |
| Trailing P/E | Infinity |
| Forward P/E | -0.96 |
| Beta | 1.39 |
| Website | https://www.akaritx.com |
As of July 11, 2026, 2:42 a.m. EDT: Speculators are overwhelmingly bearish, positioning heavy out-of-the-money puts at strikes significantly below current price while holding virtually no call interest. Implied volatility is elevated on downside protection, suggesting a consensus expectation of further decline rather than a catalyst-driven rally.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.6977477 |
| Address1 | 401 East Jackson Street |
| Address2 | Suite 3300 |
| All Time High | 95,200.0 |
| All Time Low | 3.015 |
| Ask | 13.36 |
| Ask Size | 7 |
| Average Daily Volume10 Day | 95,980 |
| Average Daily Volume3 Month | 816,175 |
| Average Volume | 816,175 |
| Average Volume10Days | 95,980 |
| Beta | 1.388 |
| Bid | 13.19 |
| Bid Size | 2 |
| Book Value | 12.563 |
| City | Tampa |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 13.42 |
| Current Ratio | 0.268 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 13.68 |
| Day Low | 13.01 |
| Debt To Equity | 5.09 |
| Display Name | Akari Therapeutics |
| Earnings Timestamp End | 1,755,892,800 |
| Earnings Timestamp Start | 1,755,547,200 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 13,301,479 |
| Eps Forward | -14.0 |
| Eps Trailing Twelve Months | 0.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 929 274 7553 |
| Fifty Day Average | 10.9201 |
| Fifty Day Average Change | 2.4998999 |
| Fifty Day Average Change Percent | 0.22892646 |
| Fifty Two Week Change Percent | -69.77477 |
| Fifty Two Week High | 49.6 |
| Fifty Two Week High Change | -36.18 |
| Fifty Two Week High Change Percent | -0.7294355 |
| Fifty Two Week Low | 3.015 |
| Fifty Two Week Low Change | 10.405 |
| Fifty Two Week Low Change Percent | 3.4510777 |
| Fifty Two Week Range | 3.015 - 49.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,389,018,600,000 |
| Float Shares | 719,362 |
| Forward Eps | -14.0 |
| Forward P E | -0.95857143 |
| Free Cashflow | -12,472,625 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 5 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.16804 |
| Held Percent Institutions | 0.09396 |
| Implied Shares Outstanding | 1,750,410 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,774,915,200 |
| Last Split Factor | 1:40 |
| Long Business Summary | Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida. |
| Long Name | Akari Therapeutics, Plc |
| Market | us_market |
| Market Cap | 23,490,502 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_306632341 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -28,048,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 23,490,497 |
| Number Of Analyst Opinions | 1 |
| Open | 13.35 |
| Operating Cashflow | -10,906,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 929 274 7510 |
| Previous Close | 13.4 |
| Price Hint | 2 |
| Price To Book | 1.0682162 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.206 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.020000458 |
| Regular Market Change Percent | 0.14925715 |
| Regular Market Day High | 13.68 |
| Regular Market Day Low | 13.01 |
| Regular Market Day Range | 13.01 - 13.68 |
| Regular Market Open | 13.35 |
| Regular Market Previous Close | 13.4 |
| Regular Market Price | 13.42 |
| Regular Market Time | 1,784,059,201 |
| Regular Market Volume | 41,390 |
| Return On Assets | -0.17969999 |
| Return On Equity | -1.55279 |
| Sand P52 Week Change | 0.2043345 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 1,750,410 |
| Shares Percent Shares Out | 0.010299999 |
| Shares Short | 17,997 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 121,540 |
| Short Name | Akari Therapeutics Plc |
| Short Percent Of Float | 0.0196 |
| Short Ratio | 0.17 |
| Source Interval | 15 |
| State | FL |
| Symbol | AKTX |
| Target High Price | 26.78 |
| Target Low Price | 26.78 |
| Target Mean Price | 26.78 |
| Target Median Price | 26.78 |
| Total Cash | 2,768,000 |
| Total Cash Per Share | 2.418 |
| Total Debt | 732,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.0 |
| Trailing P E | Infinity |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 14.363065 |
| Two Hundred Day Average Change | -0.9430647 |
| Two Hundred Day Average Change Percent | -0.06565902 |
| Type Disp | Equity |
| Volume | 41,390 |
| Website | https://www.akaritx.com |
| Zip | 33,602 |